{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:49:53Z","timestamp":1792594193413,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>ANCA-associated vasculitides (AAV) comprise a group of systemic vasculitides characterized by inflammation of small-sized blood vessels leading to multi-organ involvement. The worldwide annual incidence of AAV ranges from 1.2 to 3.3 cases per 100 000 individuals with a prevalence of 4.6\u201342.1 cases per 100 000 individuals. The prevalence of AAV is geographically heterogeneous; therefore, regional epidemiological studies can be more informative to improve health care systems. Even though clinicians are aware that the healthcare burden and the risk of hospitalization of AAV appear high, data on hospitalization and cost of illness due to AAV are still scarce or even lacking. This study aims to characterize the economic burden of AAV in Friuli Venezia Giulia (FVG), Italy. Thus, a retrospective study was conducted through the integration of many administrative health databases of the FVG as the source of information. From data integration, we estimated that more than two-thirds of AAV patients showed at least one hospitalization in their medical history, most frequently caused by the disease itself or superimposed infections. Around 10% of patients developed end-stage renal disease. In an 8-year follow-up, the overall healthcare cost was \u20ac 1,215,078, corresponding to \u20ac 6,168 patient-year. ANCA-positive patients showed much higher costs than ANCA-negative patients did. Overall, AAV are rare diseases, but imply very high healthcare costs. Early diagnosis and optimal treatment probably still remain unmet needs for AAV.<\/jats:p>","DOI":"10.1007\/s11739-020-02431-y","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T08:02:42Z","timestamp":1594713762000},"page":"581-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Healthcare and economic burden of ANCA-associated vasculitis in Italy: an integrated analysis from clinical and administrative databases"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-6439","authenticated-orcid":false,"given":"Luca","family":"Quartuccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Treppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"key":"2431_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","volume":"75","author":"D Geetha","year":"2020","unstructured":"Geetha D, Jefferson JA (2020) ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis Off J Natl Kidney Found 75:124\u2013137. https:\/\/doi.org\/10.1053\/j.ajkd.2019.04.031","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"2431_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.berh.2018.09.001","volume":"32","author":"A Berti","year":"2018","unstructured":"Berti A, Dejaco C (2018) Update on the epidemiology, risk factors, and outcomes of systemic vasculitides. Best Pract Res Clin Rheumatol 32:271\u2013294. https:\/\/doi.org\/10.1016\/j.berh.2018.09.001","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2431_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa069","author":"P Ungprasert","year":"2020","unstructured":"Ungprasert P, Koster MJ, Cheungpasitporn W et al (2020) Inpatient epidemiology and economic burden of granulomatosis with polyangiitis: a 10-year study of the national inpatient sample. Rheumatol Oxf Engl. https:\/\/doi.org\/10.1093\/rheumatology\/keaa069","journal-title":"Rheumatol Oxf Engl"},{"issue":"Suppl 117","key":"2431_CR4","first-page":"3","volume":"37","author":"S Monti","year":"2019","unstructured":"Monti S, Bond M, Felicetti M et al (2019) One year in review 2019: vasculitis. Clin Exp Rheumatol 37(Suppl 117):3\u201319","journal-title":"Clin Exp Rheumatol"},{"key":"2431_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/IJNRD.S162071","volume":"11","author":"F Arman","year":"2018","unstructured":"Arman F, Barsoum M, Selamet U et al (2018) Antineutrophil cytoplasmic antibody-associated vasculitis, update on molecular pathogenesis, diagnosis, and treatment. Int J Nephrol Renov Dis 11:313\u2013319. https:\/\/doi.org\/10.2147\/IJNRD.S162071","journal-title":"Int J Nephrol Renov Dis"},{"key":"2431_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1\u201311. https:\/\/doi.org\/10.1002\/art.37715","journal-title":"Arthritis Rheum"},{"key":"2431_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","volume":"72","author":"A Mahr","year":"2013","unstructured":"Mahr A, Katsahian S, Varet H et al (2013) Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 72:1003\u20131010. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201750","journal-title":"Ann Rheum Dis"},{"key":"2431_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102531","author":"M Scherlinger","year":"2020","unstructured":"Scherlinger M, Mertz P, Sagez F et al (2020) Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmun Rev. https:\/\/doi.org\/10.1016\/j.autrev.2020.102531","journal-title":"Autoimmun Rev"},{"key":"2431_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/0394632015617063","volume":"29","author":"A Greco","year":"2016","unstructured":"Greco A, Marinelli C, Fusconi M et al (2016) Clinic manifestations in granulomatosis with polyangiitis. Int J Immunopathol Pharmacol 29:151\u2013159. https:\/\/doi.org\/10.1177\/0394632015617063","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"Suppl 103","key":"2431_CR10","first-page":"40","volume":"35","author":"L Benarous","year":"2017","unstructured":"Benarous L, Terrier B, Laborde-Casterot H et al (2017) Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. Clin Exp Rheumatol 35(Suppl 103):40\u201346","journal-title":"Clin Exp Rheumatol"},{"key":"2431_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11926-017-0632-1","volume":"19","author":"RI Hassan","year":"2017","unstructured":"Hassan RI, Gaffo AL (2017) Rituximab in ANCA-associated vasculitis. Curr Rheumatol Rep 19:6. https:\/\/doi.org\/10.1007\/s11926-017-0632-1","journal-title":"Curr Rheumatol Rep"},{"key":"2431_CR12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40265-018-0920-8","volume":"78","author":"L Raffray","year":"2018","unstructured":"Raffray L, Guillevin L (2018) Treatment of eosinophilic granulomatosis with polyangiitis: a review. Drugs 78:809\u2013821. https:\/\/doi.org\/10.1007\/s40265-018-0920-8","journal-title":"Drugs"},{"key":"2431_CR13","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.autrev.2014.08.017","volume":"13","author":"C Comarmond","year":"2014","unstructured":"Comarmond C, Cacoub P (2014) Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev 13:1121\u20131125. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.017","journal-title":"Autoimmun Rev"},{"key":"2431_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","volume":"25","author":"ME McClure","year":"2019","unstructured":"McClure ME, Wason J, Gopaluni S et al (2019) Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 25:217\u2013223. https:\/\/doi.org\/10.1097\/RHU.0000000000001030","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"2431_CR15","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1093\/rheumatology\/kez640","volume":"59","author":"J Tieu","year":"2020","unstructured":"Tieu J, Smith R, Basu N et al (2020) Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatol Oxf Engl 59:e24\u2013e32. https:\/\/doi.org\/10.1093\/rheumatology\/kez640","journal-title":"Rheumatol Oxf Engl"},{"key":"2431_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","volume":"90","author":"L Guillevin","year":"2011","unstructured":"Guillevin L, Pagnoux C, Seror R et al (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90:19\u201327. https:\/\/doi.org\/10.1097\/MD.0b013e318205a4c6","journal-title":"Medicine (Baltimore)"},{"key":"2431_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-018-1708-7","volume":"20","author":"J Li","year":"2018","unstructured":"Li J, Cui Z, Long J-Y et al (2018) The frequency of ANCA-associated vasculitis in a national database of hospitalized patients in China. Arthritis Res Ther 20:226. https:\/\/doi.org\/10.1186\/s13075-018-1708-7","journal-title":"Arthritis Res Ther"},{"key":"2431_CR18","unstructured":"Ministero della Salute. Elenco malattie rare esentate dalla partecipazione al costo. Allegato 7 DPCM 12 gennaio 2017. https:\/\/www.trovanorme.salute.gov.it\/norme\/renderPdf.spring?seriegu=SG&datagu=18\/03\/2017&redaz=17A02015&artp=12&art=1&subart=1&subart1=10&vers=1&prog=001. Accessed 24 April 2018"},{"key":"2431_CR19","doi-asserted-by":"publisher","first-page":"m421","DOI":"10.1136\/bmj.m421","volume":"368","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Miloslavsky EM (2020) Management of ANCA associated vasculitis. BMJ 368:m421. https:\/\/doi.org\/10.1136\/bmj.m421","journal-title":"BMJ"},{"key":"2431_CR20","doi-asserted-by":"publisher","first-page":"e000435","DOI":"10.1136\/rmdopen-2017-000435","volume":"3","author":"C Heijl","year":"2017","unstructured":"Heijl C, Mohammad AJ, Westman K, H\u00f6glund P (2017) Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis. RMD Open 3:e000435. https:\/\/doi.org\/10.1136\/rmdopen-2017-000435","journal-title":"RMD Open"},{"key":"2431_CR21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41584-018-0065-x","volume":"14","author":"M McClure","year":"2018","unstructured":"McClure M, Gopaluni S, Jayne D, Jones R (2018) B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol 14:580\u2013591. https:\/\/doi.org\/10.1038\/s41584-018-0065-x","journal-title":"Nat Rev Rheumatol"},{"key":"2431_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11926-019-0835-8","volume":"21","author":"N Emejuaiwe","year":"2019","unstructured":"Emejuaiwe N (2019) Treatment strategies in ANCA-associated vasculitis. Curr Rheumatol Rep 21:33. https:\/\/doi.org\/10.1007\/s11926-019-0835-8","journal-title":"Curr Rheumatol Rep"},{"key":"2431_CR23","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/acr.22976","volume":"69","author":"ZS Wallace","year":"2017","unstructured":"Wallace ZS, Lu N, Miloslavsky E et al (2017) Nationwide trends in hospitalizations and in-hospital mortality of granulomatosis with polyangiitis. Arthritis Care Res 69:915\u2013921. https:\/\/doi.org\/10.1002\/acr.22976","journal-title":"Arthritis Care Res"},{"key":"2431_CR24","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh C-A et al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382:622\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1803537","journal-title":"N Engl J Med"},{"key":"2431_CR25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.ekir.2017.09.008","volume":"2","author":"IM Bajema","year":"2017","unstructured":"Bajema IM, Bruijn JA, Casian A et al (2017) The European vasculitis society 2016 meeting report. Kidney Int Rep 2:1018\u20131031. https:\/\/doi.org\/10.1016\/j.ekir.2017.09.008","journal-title":"Kidney Int Rep"},{"key":"2431_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.26442\/terarkh201890615-21","volume":"90","author":"NM Bulanov","year":"2018","unstructured":"Bulanov NM, Makarov EA, Shchegoleva EM et al (2018) Relationship between serologic profile (ANCA type) and clinical features of renal involvement in ANCA-associated vasculitides. Ter Arkh 90:15\u201321. https:\/\/doi.org\/10.26442\/terarkh201890615-21","journal-title":"Ter Arkh"},{"key":"2431_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/1358863X19886074","volume":"25","author":"F Valent","year":"2020","unstructured":"Valent F, Bond M, Cavallaro E et al (2020) Data linkage analysis of giant cell arteritis in Italy: Healthcare burden and cost of illness in the Italian region of Friuli Venezia Giulia (2001\u20132017). Vasc Med. 25:150\u2013156. https:\/\/doi.org\/10.1177\/1358863X19886074","journal-title":"Vasc Med."},{"key":"2431_CR28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.ekir.2018.05.007","volume":"3","author":"D Geetha","year":"2018","unstructured":"Geetha D, Jin Q, Scott J et al (2018) Comparisons of guidelines and recommendations on managing antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep 3:1039\u20131049. https:\/\/doi.org\/10.1016\/j.ekir.2018.05.007","journal-title":"Kidney Int Rep"},{"key":"2431_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/BOR.0000000000000015","volume":"26","author":"A Mahr","year":"2014","unstructured":"Mahr A, Moosig F, Neumann T et al (2014) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol 26:16\u201323. https:\/\/doi.org\/10.1097\/BOR.0000000000000015","journal-title":"Curr Opin Rheumatol"},{"key":"2431_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00281-014-0436-6","volume":"36","author":"EF McKinney","year":"2014","unstructured":"McKinney EF, Willcocks LC, Broecker V, Smith KGC (2014) The immunopathology of ANCA-associated vasculitis. Semin Immunopathol 36:461\u2013478. https:\/\/doi.org\/10.1007\/s00281-014-0436-6","journal-title":"Semin Immunopathol"},{"key":"2431_CR31","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","volume":"12","author":"D Cornec","year":"2016","unstructured":"Cornec D, Gall EC-L, Fervenza FC, Specks U (2016) ANCA-associated vasculitis\u2014clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol 12:570\u2013579. https:\/\/doi.org\/10.1038\/nrrheum.2016.123","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"2431_CR32","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.chest.2019.11.045","volume":"157","author":"A Berti","year":"2020","unstructured":"Berti A, Cornec D, Casal Moura M, Smyth RJ, Dagna L, Specks U, Keogh KA (2020) Eosinophilic granulomatosis with polyangiitis: clinical predictors of long-term asthma severity. Chest 157(5):1086\u20131099. https:\/\/doi.org\/10.1016\/j.chest.2019.11.045","journal-title":"Chest"},{"key":"2431_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00296-017-3904-1","volume":"38","author":"A Hinojosa-Azaola","year":"2018","unstructured":"Hinojosa-Azaola A, Jim\u00e9nez-Gonz\u00e1lez A, Alcocer-Castillejos N (2018) Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis. Rheumatol Int 38:631\u2013640. https:\/\/doi.org\/10.1007\/s00296-017-3904-1","journal-title":"Rheumatol Int"},{"key":"2431_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/art.1780400222","volume":"40","author":"AR Exley","year":"1997","unstructured":"Exley AR, Bacon PA, Luqmani RA et al (1997) Development and initial validation of the Vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40:371\u2013380. https:\/\/doi.org\/10.1002\/art.1780400222","journal-title":"Arthritis Rheum"},{"key":"2431_CR35","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D et al (2009) Modification and validation of the birmingham vasculitis activity score (version 3). Ann Rheum Dis 68:1827\u20131832. https:\/\/doi.org\/10.1136\/ard.2008.101279","journal-title":"Ann Rheum Dis"},{"key":"2431_CR36","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2017-21271","volume":"77","author":"JC Robson","year":"2018","unstructured":"Robson JC, Dawson J, Doll H et al (2018) Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Ann Rheum Dis 77:1157\u20131164. https:\/\/doi.org\/10.1136\/annrheumdis-2017-21271","journal-title":"Ann Rheum Dis"},{"key":"2431_CR37","doi-asserted-by":"publisher","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","volume":"30","author":"RA Watts","year":"2015","unstructured":"Watts RA, Mahr A, Mohammad AJ et al (2015) Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant 30:i14\u2013i22","journal-title":"Nephrol Dial Transplant"},{"key":"2431_CR38","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s10067-019-04463-y","volume":"38","author":"FA Pierini","year":"2019","unstructured":"Pierini FA, Scolnik M, Scaglioni V, Mollerach F, Soriano ER (2019) Incidence and prevalence of granulomatosis with polyangiitis and microscopic polyangiitis in health management organization in Argentina: a 15-year study. Clin Rheumatol 38:1935\u20131940","journal-title":"Clin Rheumatol"},{"key":"2431_CR39","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/art.24544","volume":"61","author":"RA Watts","year":"2009","unstructured":"Watts RA, Al-Taiar A, Scott DG, Macgregor AJ (2009) Prevalence and incidence of Wegener\u2019s granulomatosis in the UK General Practice Research Database. Arthritis Rheum 61:1412\u20131416","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2431_CR40","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3899\/jrheum.101149","volume":"38","author":"S Bernatsky","year":"2011","unstructured":"Bernatsky S, Linehan T, Hanly JG (2011) The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases. J Rheumatol 38(8):1612\u20131616. https:\/\/doi.org\/10.3899\/jrheum.101149","journal-title":"J Rheumatol"},{"issue":"5","key":"2431_CR41","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3899\/jrheum.101083","volume":"38","author":"S Bernatsky","year":"2011","unstructured":"Bernatsky S, Panopalis P, Pineau CA, Hudson M, St Pierre Y, Clarke AE (2011) Healthcare costs of inflammatory myopathies. J Rheumatol 38(5):885\u2013888. https:\/\/doi.org\/10.3899\/jrheum.101083","journal-title":"J Rheumatol"},{"issue":"12","key":"2431_CR42","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.3899\/jrheum.150479","volume":"42","author":"K Raimundo","year":"2015","unstructured":"Raimundo K, Farr AM, Kim G, Duna G (2015) Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States. J Rheumatol 42(12):2383\u20132391. https:\/\/doi.org\/10.3899\/jrheum.150479","journal-title":"J Rheumatol"},{"issue":"2","key":"2431_CR43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/rheumatology\/kez062.008","volume":"58","author":"M Bond","year":"2019","unstructured":"Bond M, Quartuccio L, Zandonella S, De Vita S (2019) 234 ANCA-associated vasculitis and work ability: evaluation of disease impact on working life as an outcome measure in a monocentric Italian cohort. Rheumatology (Oxford) 58(2):104. https:\/\/doi.org\/10.1093\/rheumatology\/kez062.008","journal-title":"Rheumatology (Oxford)"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-020-02431-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-020-02431-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-020-02431-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T23:54:05Z","timestamp":1626220445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-020-02431-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2431"],"URL":"https:\/\/doi.org\/10.1007\/s11739-020-02431-y","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1975 Helsinki Declaration and its later amendments or comparable ethical standards. All the patients included in the clinical database gave consent to use their own data for research purposes. This article does not contain any studies involving animals performed by any of the authors. For using anonymized administrative databases, no ethics approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}